INTRODUCTION
Corticotrophin-releasing factor (CRF-41) is a 41 amino acid peptide which was first purified from ovine hypothalami (Vale, Spiess, Rivier & Rivier, 1981) and specifically stimulates the release of adrenocorticotrophin (ACTH) in man (Grossman, Perry, Schally et al. 1982) . Screening of a human gene library with an ovine complementary DNA (cDNA) probe for CRF located the gene for the human CRF-41 precursor, from which the sequence of human CRF-41 was deduced and found to contain seven amino acid changes compared with the ovine peptide (Shibahara, Morimoto, Furutani et al. 1983 ). Secretion of CRF-41 into the hypophysial portal system is thought to be a major influence in the initiation and control of the stress response and circadian rhythm of the hypothalamo-pituitary-adrenal ( ) axis. In the rat the concentration of CRF-41 in hypophysial portal blood is increased fourfold over that in peripheral plasma (Gibbs & Vale, 1982) and high concentrations of CRF-41 have been found in the human hypothala¬ mus (Suda, Tomori, Tozawa et al. 1984 ; Ackland, Ratter, Bourne & Rees, 1986 ) and pituitary stalk (Coates, 1985) through which capillaries of the portal system extend to the anterior pituitary.
Corticotrophin-releasing factor has also been located in lesser quantities in extrahypothalamic tis¬ sues such as the adrenal cortex and medulla, the central nervous system, posterior pituitary, lung and liver (Suda et al. 1984 ) and is widespread in the gastrointestinal tract (Nieuwenhuyzen Kruseman, Lin ton, Petrusz, Merchenthaler, Maderdrut et al. 1983) . Although this peripheral CRF-41 appears to be immunologically and chromatographically similar to hypothalamic CRF-41, it is not known whether it is secreted into the circulation and whether it plays any role in the control of ACTH secretion.
Three reports measuring the concentrations of CRF-41 ih human plasma have appeared (Linton & Lowry, 1985; Suda, Tomori, Yajima et al. 1985 ; Charlton, Leake, Ferrier et al. 1986 ). In one (Charlton et al. 1986) (Sasaki, Liotta, Luckey et al. 19846; Stalla, Hartwimmer, von Werder & Muller, 1984; Linton, Campbell, Wolfe et al. 1986 ). Corticotrophinreleasing factor has been found in significant amounts in human placenta (Sasaki, Liotta & Krieger, 1984 ) which may be the source of the circulating material. We have subjected pregnancy plasma and placental tissue to Chromatographie analysis and include a comparative study of CRF immunoreactivity in this report.
MATERIALS AND METHODS

Measurement of CRF-41
Collection ofplasma Venous blood samples (10 ml) were collected into lithium heparin tubes containing 0-5 ml Trasylol (10 000 KIU; Bayer UK Ltd, Hay wards Heath, Sussex). Plasma was separated immediately by centrifugation at 4°C, flash-frozen and stored at -20°C. Samples were taken at 09.00 h from fasted normal volunteers unless otherwise stated.
Plasma extraction
The method utilizing Vycor glass was a modification ofthat employed by Rees, Cook, Kendall et al. (1971) (Skowsky & Fisher, 1972) and injected into New Zealand White rabbits (Ackland et al. 1986 ). Antiserum (50 pi) was added to each assay tube (final dilution 1:48 000) and incubated for 24 h at 4°C. Syn¬ thetic Tyr-CRF-41 (Bachern) was iodinated with 125I by the chloramine method (Hunter & Greenwood, 1962) (Edwards, 1983 
Radioimmunoassay of CRF-41
The antiserum would appear to be directed towards the mid-portion of CRF-41 as it did not cross-react with fragments of synthetic human and (36) (37) (38) (39) (40) (41) . The antiserum did not cross-react with any other relevant human peptide examined (gastrinreleasing peptide( 14-27), growth hormone-releasing factor(l-40), luteinizing hormone-releasing hormone, Radioimmunoassay of cortisol The assay range was 50-2000 nmol/1. Cross-reactivity of the antiserum with related steroids was: prednisolone, 19%; 11-deoxycortisol, 0-45% and all other steroids and steroid conjugates, <0-05%. Interassay precision at 100, 300 and 1000 nmol/1 was 13, 7-4 and 7% respectively.
Plasma concentrations of CRF-41
The normal range of CRF-41 (46 subjects, age range 20-50 years) was < 20-110 ng/1. In plasma from a normal subject extracted and subjected to RPHPLC, a single peak of CRF-41 was detected which co- (Fig. 3) (Fig. 4) . There was considerable variation in CRF-41 concentrations with time in individual sub¬ jects but this was not related to the period of hypo¬ glycaemia (Fig. 5) (Fig. 9) (Linton & Lowry, 1985) and an RIA after prior extraction of CRF-41 by an immunoaffinity procedure (Suda et al. 1985) . (Rees, Burke, Chard et al. 1975 ). This rise, together with increasing urinary concentrations of cortisol, was resistant to dexamethasone suppression. Plasma concentrations of free cortisol are also reported to be increased in the second and third trimesters (Abou-Samra, Pugeat, Dechaud et al. 1984) . Despite these findings, and a single case report implicating pregnancy as a cause of Cushing's syndrome (Wieland, Shaffer & Glove, 1971 (Udelsman, Harwood, Millan et al. 1986 ), and CRF-41 has been shown to stimulate the release of pancreatic poly¬ peptide in man (Lytras, Grossman, Rees et al. 1984 ).
We propose, therefore, that tissues other than the hypothalamus may synthesize and secrete some of the CRF-41 found in human plasma and that this peptide may have a biological function in peripheral tissues.
